Instructions / Instruction for use: OlanzapineI want this, give me price
Dosage form: substance powder
Active substance: Olanzapine*
The nosological classification (ICD-10)
F20 Schizophrenia: Schizophrenic conditions; Exacerbation of schizophrenia; Schizophrenia; Chronic schizophrenia; Dementia praecox; Bleuler's disease; Psychotic discordant; Dementia early; The febrile form of schizophrenia; Chronic schizophrenic disorder; Psychosis of the schizophrenic type; Acute form of schizophrenia; Acute schizophrenic disorder; Cerebral Organic Insufficiency in Schizophrenia; Acute attack of schizophrenia; Schizophrenic psychosis; Acute schizophrenia; Sluggish schizophrenia; Sluggish schizophrenia with apathoabulic disorders; Acute stage of schizophrenia with excitation
F30 Manic episode: Manic-depressive disorder; Manic agitation; Manic state; Manic conditions; A manic condition; Manic syndrome; Acute manic syndrome
F31 Bipolar affective disorder: Mood disorders bipolar; Affective bipolar psychosis; Manic-melancholic psychosis; Intermittent psychosis; Circular psychosis; Cyclophrenia; Bipolar disorders; Bipolar psychosis; Affective insanity; Manic-depressive syndrome; Psycho Manic-Depressive; Depressive episode of bipolar disorder
F32 Depressive episode: Adynamic subdepression; Astheno-adynamic subdepressive states; Asthenodepressive disorder; Astheno-depressive disorder; Asthenodepressive state; Astheno-depressive state; Major Depressive Disorder; Vyaloapatichesky depression with retardation; Double depression; Depressive pseudodement; Depressive illness; Depressive mood disorder; Depressive disorder; Depressive mood disorder; Depressive state; Depressive disorders; Depressive syndrome; Depressive syndrome larviated; Depressive syndrome with psychoses; Depressed masks; Depression; Depression Depletion; Depression with the phenomena of inhibition within the framework of cyclothymia; Depression is smiling; Involutional depression; Involutionary melancholy; Involutional depression; Manic-depressive disorder; Masked Depression; Melancholic Attack; Neurotic depression; Neurotic depression; Shallow Depression; Organic depression; Organic depressive syndrome; Simple depression; Simple melancholic syndrome; Psychogenic depression; Reactive depression; Reactive depression with moderate psychopathological symptoms; Reactive depressive states; Reactive depression; Recurrent depression; Seasonal depressive syndrome; Severostatic depression; Senile Depression; Senile Depression; Symptomatic Depression; Somatogenic depression; Cyclotymic depression; Exogenous Depression; Endogenous depression; Endogenous Depressive Conditions; Endogenous Depression; Endogenous depressive syndrome
F33 Recurrent depressive disorder: Major depressive disorder; Secondary depression; Double depression; Depressive pseudodement; Depressive mood disorder; Depressive disorder; Depressive mood disorder; Depressive state; Depressive syndrome; Depressed masks; Depression; Depression is smiling; Involutional depression; Involutional depression; Masked Depression; Melancholic Attack; Reactive depression; Reactive depression with moderate psychopathological symptoms; Reactive depressive states; Exogenous Depression; Endogenous depression; Endogenous Depressive Conditions; Endogenous Depression; Endogenous depressive syndrome
Tablets 1 table.
olanzapine 5 mg; 10 mg
auxiliary substances: lactose monohydrate (sugar milk) - 50,6 / 101,2 mg; MCC - 51.4 / 102.8 mg; pregelatinized starch - 51.4 / 102.8 mg; silicon dioxide colloid (aerosil) - 0.8 / 1.6 mg; magnesium stearate - 0.8 / 1.6 mg
Pharmacological action - antipsychotic.
Dosing and Administration
Inside, regardless of food intake, tk. food does not affect the absorption of olanzapine.
Schizophrenia. The recommended initial dose of olanzapine is 10 mg once a day. Therapeutic doses of olanzapine range from 5 to 20 mg / day. The daily dose must be selected individually, depending on the clinical condition of the patient. Dose increase above the standard daily (10 mg) is recommended only after an assessment of the clinical picture. When using the drug should regularly assess the need for continued therapy.
Bipolar disorder. For the treatment of the manic episode, the recommended initial dose of olanzapine is 15 mg once a day as monotherapy or 10 mg once a day in combination with lithium or valproic acid. Therapeutic doses of olanzapine range from 5 to 20 mg / day. The daily dose must be selected individually, depending on the clinical condition of the patient. An increase in the dose above the standard daily is recommended only after assessment of the clinical picture and with an interval of at least 24 hours.
Supportive therapy for bipolar disorder: patients who took olanzapine for the treatment of a manic episode should continue supporting therapy at the same dose. In patients in remission, the recommended initial dose of olanzapine is 10 mg once a day. In the future, the daily dose should be selected individually, depending on the clinical state of the patient, ranging from 5 to 20 mg / day.
To treat a depressive episode, olanzapine should be given in combination with fluoxetine once a day, in the evening, regardless of food intake. Typically, the initial dose is 5 mg of olanzapine and 20 mg of fluoxetine. Antidepressant activity was confirmed with olanzapine 6-12 mg (mean daily dose 7.4 mg) and fluoxetine 25-30 mg (mean daily dose 39.3 mg). If necessary, you can change the dose of both olanzapine and fluoxetine. When using the drug, it is necessary to regularly evaluate the need for continuing therapy.
Therapeutically resistant depression. Olanzapine should be prescribed in combination with fluoxetine 1 time per day, in the evening, regardless of food intake. Typically, the initial dose is 5 mg of olanzapine and 20 mg of fluoxetine. If necessary, you can change the dose of both olanzapine and fluoxetine. Antidepressant activity was confirmed with olanzapine 6-12 mg and fluoxetine at a dose of 25-30 mg. When using the drug, it is necessary to regularly evaluate the need for continuing therapy.
General rules for choosing a daily dose for special groups of patients with oral intake
Reduction of the initial dose to 5 mg / day is recommended for elderly patients or patients with other clinical risk factors, including severe renal failure or moderate-level liver failure.
A reduction in the initial dose of up to 5 mg can be recommended for patients with a combination of factors (female gender, advanced age and lack of smoking habits) that can reduce the metabolism of olanzapine.
The use of olanzapine has not been studied in persons younger than 13 years.
Shelf life of the drug Olanzapine
Do not use after the expiry date printed on the package.